

SUPPLEMENTARY INFORMATION

**Micellar catalysis of the Suzuki Miyaura reaction using  
biogenic Pd nanoparticles from *Desulfovibrio alaskensis***

**Yuta Era, Jonathan A. Dennis, Stephen Wallace\* and Louise E. Horsfall\***

*Institute of Quantitative Biology, Biochemistry and Biotechnology, School of Biological Sciences,  
University of Edinburgh, Roger Land Building, Alexander Crum Brown Road, King's Buildings,  
Edinburgh, EH9 3FF*

\*Correspondence to: [louise.horsfall@ed.ac.uk](mailto:louise.horsfall@ed.ac.uk); [stephen.wallace@ed.ac.uk](mailto:stephen.wallace@ed.ac.uk)

## Supplementary Materials

<b>S1</b>	<b>General materials and methods</b> .....	S2
<b>S2</b>	<b>Strain, media and culture condition</b> .....	S3
<b>S3</b>	<b>DaPdNPs production by <i>Desulfovibrio alaskensis</i></b> .....	S3
	<i>Fig. S1</i> Representative Electron micrographs of DaPdNPs	
	<i>Fig. S2</i> XRD pattern of the DaPdNPs synthesised by <i>D. alaskensis</i>	
	<i>Fig. S3</i> ICP standard curve	
<b>S4</b>	<b>General Suzuki coupling reaction</b> .....	S5
	<i>Fig. S4</i> Representative <sup>1</sup> H NMR spectra	
	<i>Fig. S5</i> Result of control experiments	
<b>S5</b>	<b>Coupling reaction optimisation in aqueous solution</b> .....	S7
	<i>Table S1</i> Ligand/additive and halides screen	
<b>S6</b>	<b>Coupling reaction with chemically produced Pd catalysts</b> .....	S8
	<i>Table S2</i> Coupling reaction promoted by chemically made Pd catalysts	
<b>S7</b>	<b>Micellar coupling reaction in the presence of various ligands</b> .....	S8
	<i>Table S3</i> Micellar coupling reaction in the presence of various ligands	
<b>S8</b>	<b>Effect of TPGS-1000 on the reaction speed and the catalyst loading minimisation</b> .....	S9
	<i>Table S4</i> Time-course experiments and catalyst loading optimisation without TPGS-1000	
<b>S9</b>	<b>Investigation of the reaction scope</b> .....	S10
	<i>Table S5</i> Reaction scope	
<b>S10</b>	<b>Three-phase test</b> .....	S13
	<i>Fig. S6</i> Three-phase test	
	<i>Table S6</i> Three-phase test	
<b>S11</b>	<b>TEM analysis of DaPdNPs and TPGS micelles</b> .....	S14
	<i>Fig. S7</i> Negative stained DaPdNPs in the presence of 0.4% w/v TPGS-1000	
	<i>Fig. S8</i> Negative stained DaPdNPs in the presence of 0.4% w/v TPGS-750-M	
<b>S12</b>	<b>Product and Pd separation</b> .....	S17
	<i>Fig. S9</i> Pelleted DaPdNPs during liquid-liquid extraction	
<b>S13</b>	<b>Product characterisation</b> .....	S18
<b>S14</b>	<b>References</b> .....	S25

## S1 General materials and methods

Unless otherwise noted, starting materials and reagents were obtained from commercial suppliers and were used without further purification. All water used experimentally was purified with a Suez Select purification system (18 mΩ/cm, 0.2 μM filter).

**NMR and IR:** Proton nuclear magnetic resonance spectra (<sup>1</sup>H NMR) were recorded using an AVA 500 NMR spectrometer (Bruker) at the specified frequency at 298K. Proton chemical shifts are expressed in parts per million (ppm, δ scale) and are referenced to residual protium in the NMR solvent (CDCl<sub>3</sub>, δ 7.26 ppm). Coupling constants, *J*, are measured to the nearest 0.1 Hz and are presented as observed. Data is represented as: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublet, m = multiplet and/or multiple resonances), coupling constant (J) in Hertz. NMR solvents were used as purchased from commercial suppliers. For all quantitative NMR measurements, 1,3,5-trimethoxybenzene (TMB) was used as an internal standard. Infrared (IR) spectroscopy was performed using a Spectrum Two IR spectrometer (Perkin Elmer).

**XRD:** X-ray diffraction experiments were recorded on a MiniFlex 600 benchtop X-ray diffractometer (Rigaku) with D/teX Ultra 1D silicon strip detector (Rigaku) using CuKα radiation. Scanning was run at a 2θ angle from 20 to 100° with a 2° step size (40 kV, 15 mA).

**ICP-OES:** Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES) was performed using an Optima 8300 instrument (Perkin Elmer). Experiments were performed using the following conditions: samples were sonicated for 30 min at 21 °C in a water bath and then centrifuged (20,000 × g, 2 h). The supernatant (the ionic fraction) was added to a solution of aqua regia (HCl:HNO<sub>3</sub> = 14:10%) and heated to 80°C for 8 h. The resulting sample was diluted in 2% nitric acid to a final volume of 3 mL and used immediately. Unspun samples (whole fraction) were prepared using an analogous method. When quantifying by ICP a standard curve was constructed over a range of analyte concentrations (0.04–10 ppm) providing linear relationships of Intensity = 41356c<sub>Pd</sub> + 1573.4.

**TEM:** Transmission electron microscopy (TEM) was performed using a JEM-1400 Plus (JEOL) with an accelerating voltage of 80 kV. TEM images were captured using a GATAN OneView camera. Image processing was carried out using ImageJ software. Experiments were performed using the following conditions: suspensions of *Da*PdNPs were drop cast on to a 200 mesh carbon-coated copper grid and dried for 5 min under air. The excess liquid was then removed and the samples visualised immediately using a TEM (JEM-1400 Plus, JEOL) with an accelerating voltage of 80 kV.

## **S2 Strain, media, buffer and culture condition**


*Desulfovibrio alaskensis* G20 (DSM 17464) was obtained from DSMZ. *Desulfovibrio alaskensis* G20 (DSM 17464) was grown statically on de-gassed Postgate Medium C at 30 °C in an anaerobic chamber fed with 10% H<sub>2</sub> and 10% CO<sub>2</sub> in nitrogen. Optical densities of *D. alaskensis* cultures were determined using a WPA CO8000 spectrophotometer (Biochorm) by measuring absorbance at 600 nm.

Postgate Medium C was prepared according to the following procedure: KH<sub>2</sub>PO<sub>4</sub> (0.5 g), NH<sub>4</sub>Cl (1.0 g), Na<sub>2</sub>SO<sub>4</sub> (4.5 g), CaCl<sub>2</sub>·6H<sub>2</sub>O (0.06 g), MgSO<sub>4</sub>·7H<sub>2</sub>O (0.06 g), 60% sodium lactate (10 mL) yeast extract (1.0 g), FeSO<sub>4</sub>·7H<sub>2</sub>O (0.004 g) and sodium citrate·2H<sub>2</sub>O (0.3 g) were dissolved in 990 mL ultrapure water and its pH was adjusted to 7.5 using 2 M NaOH. The medium was autoclaved at 121 °C for 20 min and cooled to room temperature. Autoclaved Postgate Medium C was stored at room temperature and degassed in the anaerobic chamber overnight before the use.


MOPs buffer was prepared according to the following procedure: MOPs free acid (41.86 g) was dissolved in 1 L ultrapure water and its pH was adjusted to 7.0 using 1 M H<sub>2</sub>SO<sub>4</sub>. The buffer was autoclaved at 121 °C for 20 min and cooled to room temperature. Autoclaved MOPs buffer was stored at room temperature and degassed in the anaerobic chamber overnight before the use.

## **S3 DaPdNPs production by *Desulfovibrio alaskensis***


*D. alaskensis* cells were pre-grown following previously reported methods<sup>[1]</sup>, recovered and washed with MOPs buffer three times prior to inoculation (to a final OD<sub>600</sub> of 1.0) in 50 mL centrifuge tubes containing 40 mL MOPs buffer. Freshly made Na<sub>2</sub>PdCl<sub>4</sub> stock solution (40 mM in H<sub>2</sub>O) was added to the cell suspension to a final concentration of 2 mM. The centrifuge tubes were incubated at 30 °C for 20 h in an anaerobic chamber. The biogenic nanoparticles (*DaPdNPs*) were harvested by centrifugation at 15 min, 4,500 × g and washed with 50% acetone in H<sub>2</sub>O (1 x vol equiv.). Subsequently, the *DaPdNPs* were freeze-dried overnight, resuspended in ultrapure water and sonicated in a water bath for 30 min. The resulting nanoparticles were analysed by XRD and TEM. The recovery of Pd as *DaPdNPs* was determined by ICP-OES.



*Fig. S1* Representative Electron micrographs of DaPdNPs.




*Fig. S2* XRD pattern of the DaPdNPs synthesised by *D. alaskensis*. The symbol ○ is assigned to palladium (JCPDS 87-0641).




**Fig. S3** ICP standard curve used for the quantification of palladium recovered as DaPdNP. DaPdNP was ionised with aqua regia prior to the analysis.

#### S4 General Suzuki coupling reaction

Cross coupling reactions were carried out using the following procedure: DaPdNPs were added to a 15 mL Hungate tube containing aryl halide (25 mM), phenyl boronic acid (30 mM),  $K_2CO_3$  (30 mM) and TPGS-1000/TPGS-750-M (2% w/v) in  $H_2O$  (5 mL). The tubes were sealed with butyl rubber septa and screw-caps and incubated at 37 °C (200 rpm) for 20 h in a New Brunswick Innova 44 incubator shaker (Eppendorf). After this time, the reactions were cooled to room temperature, extracted with methyl *tert*-butyl ether (MTBE, 3 x 1.7 mL) and concentrated under reduced pressure. The crude residue was dissolved in 1 mL  $CDCl_3$  containing 10 mM TMB and analysed by  $^1H$  NMR spectroscopy.



**Fig. S4** Representative  $^1\text{H}$  NMR spectra.







**Fig. S5** Result of control experiments. Full reaction was conducted using DaPdNPs (0.25 mM), 4-bromoanisole (25 mM), phenylboronic acid (30 mM),  $\text{K}_2\text{CO}_3$  (30 mM) and TPGS-1000 (2% w/v) in  $\text{H}_2\text{O}$  (5 mL).

## S5 Coupling reaction optimisation in aqueous solution

Unless otherwise noted, model reaction (*DaPdNPs* (0.25 mM), 4-bromanisole (25 mM), phenylboronic acid (30 mM),  $K_2CO_3$  (30 mM) in  $H_2O$  (5 mL)) was used by following the above protocol for reaction optimisation and screening experiments. For ligand/additive screening, triphenylphosphine ( $PPh_3$ ), JohnPhos, SPhos, XPhos, sSPhos, 4-aminopyridine-2,6-diol (AmPyol), 1,1,3,3-tetramethylguanidine (TMG) or green tea polyphenols was added to the model reaction (2.5 mM for ligands and 0.1/ or 0.01 % w/v for green tea polyphenols). For halide screening, 4-chloroanisole/4-iodoanisole (25 mM) was used as the coupling partner instead of 4-bromoanisole.

**Table S1** Ligand/additive and halides screen



#	Ar-X	Ar-B(OH) <sub>2</sub>	Ligand	<i>DaPdNPs</i> loading (mol%)	Additive	Yield	
						mM	±SD
1			–	1.0	–	8.4	3.8
2			$PPh_3$			6.0	0.3
3			JohnPhos			9.0	1.1
4			SPhos			8.1	1.9
5			XPhos			14.0	1.8
6			TMG			15.6	1.4
7			AmPyol			5.0	0.5
8			sSPhos			1.6	0.2
9			–		Green tea polyphenols (0.1% w/v)	0.4	0.1
10			–		Green tea polyphenols (0.01% w/v)	6.4	0.5
11			–	1.0	–	9.0	0.5
12			–	1.0	–	0.2	0.0

The yield shown above is the average of triplicate experiments.

## S6 Coupling reaction with chemically produced Pd catalysts

Chemically produced Pd nanoparticle (cPdNP, 0.25 mM) or Pd on activated carbon (Pd/C, 0.25 mM) was added to the model reaction with/without ligands (XPhos or TMG, 2.5 mM) in place of DaPdNPs. The reactions were conducted and analysed by following the protocol in Section S4.

**Table S2** Coupling reaction promoted by chemically made Pd catalysts



#	Ar-X	Ar-B(OH) <sub>2</sub>	Ligand	Pd catalyst	Additive	Yield	
						mM	±SD
1			–	cPdNPs	–	0.2	0.2
2			XPhos			0.2	0.0
3			TMG			0.3	0.2
4			–	Pd/C		0.1	0.0
5			XPhos			1.3	0.5
6			TMG			0.4	0.7

The yield shown above is the average of triplicate experiments.

## S7 Micellar coupling reaction in the presence of various ligands

The model reaction containing no ligand, JohnPhos, SPhos, XPhos or TMG (2.5 mM) was conducted in the presence of TPGS-750-M or TPGS-1000 (2% w/v). The reactions were conducted and analysed by following the protocol in Section S4.

**Table S3** Micellar coupling reaction in the presence of various ligands







#	Ar-X	Ar-B(OH) <sub>2</sub>	Ligand	DaPdNPs loading (mol%)	Additive	Yield	
						mM	±SD
1			–	1.0	TPGS-750-M	20.8	1.4
2					TPGS-1000	>25	0.7
3			JohnPhos		TPGS-750-M	11.1	1.0
4					TPGS-1000	22.2	1.0
5			SPhos		TPGS-750-M	12.0	0.9
6					TPGS-1000	18.3	0.7
7 <sup>[a]</sup>			XPhos		TPGS-750-M	21.5	2.1
8					TPGS-1000	>25	2.2
9			TMG		TPGS-750-M	19.3	0.9
10					TPGS-1000	24.9	1.0


The yield shown above is the average of triplicate experiments ([a]: duplicate).

### S8 Effect of TPGS-1000 on the reaction speed and the catalyst loading minimisation

Reactions containing TPGS-1000 (2% w/v) or no surfactant and either no ligand, XPhos or TMG (2.5 mM) was sealed and incubated at 37 °C (200 rpm) in a New Brunswick Innova 44 incubator shaker (Eppendorf). Reactions were collected at 1, 2, 4, 20 and 40 h, and extracted with extracted with MTBE (3 x 1.7 mL) immediately. For the catalyst loading minimisation experiment, the concentration of *Da*PdNPs was adjusted to 0.01, 0.05, 0.1, 0.5 or 1.0 in the ligand-free model reaction with/without TPGS-1000 (2% w/v). The reactions and catalyst-free control reaction were sealed and incubated at 37 °C (200 rpm) for 20 h. The following analysis was carried out as outlined in Section S4.

**Table S4** Time-course experiments and catalyst loading optimisation without TPGS-1000

#	Ar-X	Ar-B(OH) <sub>2</sub>	Ligand	Reaction time (h)	<i>Da</i> PdNPs loading (mol%)	Additive	Yield	
							mM	±SD
1			-	1	1.0	-	1.3	0.4
2				1.8			0.9	
3				5.0			0.9	
4				8.4			3.8	
5				7.0			4.8	
6				TPGS-1000			11.7	3.2
7							21.0	0.7
8							22.5	3.5
9							>25	0.8
10							>25	1.0
11			XPhos	1	1.0	-	0.8	0.2
12				0.9			0.7	
13				1.5			0.9	
14				9.4			2.3	
15				6.7			1.4	
16				TPGS-1000			4.6	0.4
17							18.4	3.1
18							>25	1.1
19							>25	0.5
20							>25	2.0
21			TMG	1	1.0	-	5.2	0.7
22				8.2			1.4	
23				11.3			1.6	
24				15.6			1.4	
25				14.8			2.6	














26				1		TPGS-1000	10.7	0.6
27				2			21.5	1.6
28				4			23.2	3.0
29				20			>25	2.4
30				40			>25	1.2
31			-	20	0	-	N.D.	N.A.
32					0.01		0.2	0.2
33					0.05		0.5	0.3
34					0.1		1.0	0.7
35					0.5		4.7	4.3
36					1.0		6.2	4.5
37				20	0	TPGS-1000	N.D.	N.A.
38					0.01		0.1	0.1
39					0.05		0.6	0.2
40					0.1		7.7	3.2
41					0.5		>25	0.2
42					1.0		>25	1.5

The yield shown above is the average of triplicate experiments (N.D.: Not detected, N.A.: Not applicable).






### S9 Investigation of the reaction scope

Aryl bromide (4-bromoacetophenone, 3-bromoacetophenone, 2-bromoacetophenone, 1-bromo-4-nitrobenzene or 4-bromophenol: 25 mM) and boronic acid (*p*-tolylboronic acid, 2-methoxy-3-pyridinylboronic acid, 4-ethoxyphenylboronic acid, 3-ethoxyphenylboronic acid, 3-ethoxyphenylboronic acid :30 mM) were added to Hungate tube containing *DaPdNPs* (0.25 mM) and  $K_2CO_3$  (30 mM) in  $H_2O$  (5 mL). Reactions of 25 different cross-coupling combination were carried out and analysed as outlined in Section S4. Subsequently, for the reactions resulting in less than 80% yield, the identical coupling reactions were conducted in the presence of TPGS-1000 (2% w/v).

**Table S5** Reaction scope

#	Ar-X	Ar-B(OH) <sub>2</sub>	Ligand	DaPdNPs loading (mol%)	Additive	Yield	
						mM	±SD
1			-	1.0	-	>25	1.5
2					-	21.6	1.7
3					-	>25	1.5
4					-	>25	0.2
5					-	>25	1.1
6			-	1.0	-	>25	0.6
7					-	12.5	5.3
8 <sup>[b]</sup>					TPGS-1000	24.3	N.A.
9					-	>25	1.5
10					-	>25	1.3
11					-	>25	1.5


12 <sup>[a]</sup>			-	1.0	-	11.3	0.5	
13 <sup>[a]</sup>					TPGS-1000	12.1	3.9	
14					-	N.D.	N.A.	
15					TPGS-1000	N.D.	N.A.	
16 <sup>[a]</sup>						-	4.1	0.3
17 <sup>[a]</sup>					TPGS-1000	9.4	0.4	
18						-	4.5	0.1
19					TPGS-1000	4.8	0.0	
20						-	0.9	0.2
21					TPGS-1000	2.0	0.2	
22						-	1.0	-
23 <sup>[a]</sup>			-	3.7	0.0			
24 <sup>[a]</sup>			TPGS-1000	18.1	0.2			
25				-	21.2			1.7
26				-	24.6			2.0
27 <sup>[a]</sup>				-	17.7			0.6
28 <sup>[a]</sup>			TPGS-1000	18.8	0.7			
29				-	1.0			-

30			-	1.0	-	4.0	0.4
31 <sup>[a]</sup>		TPGS-1000			10.2	0.6	
32					-	18.6	1.7
33		TPGS-1000			21.3	0.6	
34					-	23.0	0.5
35 <sup>[a]</sup>					-	N.D.	N.A.
36 <sup>[a]</sup>		TPGS-1000			10.6	0.7	

The yield shown above is the average of triplicate experiments ([a]: duplicate, [b]: no replicate, N.D.: Not detected, N.A.: Not applicable).

### S10 Three-phase test

For the solid support, the Wang resin, a polystyrene based resin with a p-benzyloxybenzyl alcohol linker often used in solid phase peptide synthesis was chosen<sup>[2]</sup>. Iodobenzoic acid bound to a Wang resin was synthesised according to the following procedure: Wang resin (2.0 g, 1.0 mmol/g loading) was added to a solution of dichloromethane:*N,N*-dimethylformamide (9:1, 20 mL) and stirred for 15 min. *N,N'*-diisopropylcarbodiimide (930  $\mu$ L, 300 mM), 4-iodobenzoic acid (2.5 g, 500 mM) and 4-(dimethylamino)pyridine (1.0 mg, 0.4 mM) were added to the mixture and the reaction was stirred for 3 days at room temperature (21 °C). The resin was recovered by filtration, washed with dichloromethane (3 x 20 mL) and dried under vacuum. Formation of the target compound was confirmed by the appearance of a characteristic ester stretch in the IR spectrum of the product at 1615  $\text{cm}^{-1}$ . For the three-phase test, polymer-supported iodobenzoic acid was added in place of haloaryls following standard cross-coupling reaction conditions. After incubation, the solid was collected by vacuum filtration, washed with dichloromethane (4 x 5.0 mL), dried under vacuum, dissolved in TFA:dichloromethane (9:1, 2.0 mL) and stirred at room temperature for 2 h. The resin was collected by vacuum filtration and washed with dichloromethane (4 x 5.0 mL). The combined organic layers were concentrated under reduced pressure. Control reactions were conducted using methyl 4-iodobenzoate (33 mg, 25 mM, 1.0 equiv) instead of the polymer-supported iodobenzoic acid and analysed according to the general procedure outlined in Section S4.



**Fig. S6** Three-phase test


**Table S6** Three-phase test

#	Ar-X	Ar-B(OH) <sub>2</sub>	Ligand	<i>Da</i> PdNPs loading (mol%)	Additive	Yield	
						mM	±SD
1			—	1.0	—	N.D.	N.A.
2			—	1.0	—	12.2	3.5


The yield shown above is the average of duplicate experiments (N.D.: Not detected, N.A.: Not applicable).

### S11 TEM analysis of *Da*PdNPs and TPGS micelles

Samples were prepared for TEM analysis by incubating *Da*PdNPs (0.25 mM) and TPGS-1000 or TPGS-750-M (0.4% w/v) in H<sub>2</sub>O at 37 °C (220 rpm) for 12 h. One drop was then transferred on to a Formvar/Carbon 200 mesh Copper grid and left to dry in air for 10 min. Excess solution was removed by touching the grid edge with filter paper. A drop of 1% aqueous uranyl acetate was applied for 1 minute and then removed by touching the grid edge with filter paper. TEM observation was carried out as described in Section S1.




**Fig. S7** Negative stained DaPdNPs in the presence of 0.4% w/v TPGS-1000



**Fig. S8** Negative stained DaPdNPs in the presence of 0.4% w/v TPGS-750-M

## S12 Product and Pd separation


The model reaction containing TPGS-1000 was conducted, extracted and concentrated as described above. The crude residue was dissolved in 10% ethanol (5 mL). An aliquot of the filtered solution (1 mL) was diluted in 1-methoxy-2-propanol to a final volume of 5 mL and analysed by ICP-OES immediately. As a result, no detectable amount of Pd was quantified in the sample (the calculated LoD<sup>[3]</sup>: 0.02  $\mu$ M). This demonstrated the cross-coupling product can be easily separated from *DaPdNPs* catalyst in the extraction process, meaning no extra separation steps are required.



**Fig. S9** Pelleted *DaPdNPs* during liquid-liquid extraction

## S13 Product Characterisation


### 4-Methoxybiphenyl



$^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 7.31\text{--}7.25$  (m, 2H),  $7.27\text{--}7.24$  (m, 2H),  $7.17\text{--}7.10$  (m, 2H),  $7.06\text{--}6.98$  (m, 1H),  $6.80\text{--}6.62$  (m, 2H),  $3.57$  (s, 3H).

Spectroscopic data in good agreement with the literature.<sup>[4]</sup>


### 4'-Methyl-4-biphenylcarboxylate



$^1\text{H NMR}$  (500 MHz, DMSO):  $\delta = 8.15\text{--}8.08$  (m, 2H),  $7.91\text{--}7.85$  (m, 2H),  $7.74\text{--}7.68$  (m, 2H),  $7.43\text{--}7.36$  (m, 2H),  $3.97$  (s, 3H),  $2.45$  (s, 3H).

Spectroscopic data in good agreement with the literature.<sup>[5]</sup>


### 1-(4'-Methyl-4-biphenyl)ethenone



$^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.13\text{--}8.09$  (m, 2H),  $7.78\text{--}7.74$  (m, 2H),  $7.66\text{--}7.60$  (m, 2H),  $7.41\text{--}7.35$  (m, 2H),  $2.72$  (s, 3H),  $2.51$  (s, 3H).


Spectroscopic data in good agreement with the literature.<sup>[5]</sup>

### 1-[4-(2-Methoxy-3-pyridinyl)phenyl]ethenone




$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.30$  (dd,  $J = 4.9, 1.9$ , 1H), 8.17–8.05 (m, 2H), 7.78–7.75 (m, 2H), 7.74 (dd,  $J = 7.3, 1.9$ , 1H), 7.10 (dd,  $J = 7.3, 5.0$ , 1H), 4.09 (s, 3H), 2.74 (s, 3H). Spectroscopic data in good agreement with the literature.<sup>[6]</sup>

### 1-(4'-Ethoxy-4-biphenyl)ethenone




$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.13$ –8.05 (m, 2H), 7.76–7.71 (m, 2H), 7.70–7.61 (m, 2H), 7.10–7.06 (m, 2H), 4.19 (q,  $J = 7.0$ , 2H), 2.72 (s, 3H), 1.55 (t,  $J = 7.0$ , 3H). Spectroscopic data in good agreement with the literature.<sup>[7]</sup>

### 1-(3'-Ethoxy-4-biphenyl)ethenone




$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.17$ –8.03 (m, 2H), 7.81–7.69 (m, 2H), 7.47 (t,  $J = 7.9$ , 1H), 7.29 (ddd,  $J = 7.6, 1.8, 0.9$ , 1H), 7.25 (dd,  $J = 2.5, 1.7$ , 1H), 7.03 (ddd,  $J = 8.3, 2.5, 0.9$ , 1H), 4.20 (q,  $J = 7.0$ , 2H), 2.73 (s, 3H), 1.55 (t,  $J = 7.0$ , 3H).

### 1-(2'-Ethoxy-4-biphenyl)ethenone




$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta = 8.11$ –8.07 (m, 2H), 7.79–7.71 (m, 2H), 7.51–7.40 (m, 2H), 7.13 (td,  $J = 7.5, 1.1$ , 1H), 7.11–7.03 (m, 1H), 4.15 (q,  $J = 7.0$ , 2H), 2.73 (s, 3H), 1.45 (t,  $J = 7.0$ , 3H).

### 1-(4'-Methyl-3-biphenyl)ethenone




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.27 (t,  $J$  = 1.8, 1H), 8.01 (dt,  $J$  = 7.7, 1.5, 1H), 7.87 (ddd,  $J$  = 7.7, 1.9, 1.1, 1H), 7.64–7.59 (m, 3H), 7.37 (d,  $J$  = 7.8, 2H), 2.75 (s, 3H), 2.51 (s, 3H).  
Spectroscopic data in good agreement with the literature.<sup>[5]</sup>

### 1-[3-(2-Methoxy-3-pyridinyl)phenyl]ethenone




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.30 (dd,  $J$  = 5.0, 1.9, 1H), 8.24 (t,  $J$  = 1.7, 1H), 8.04 (ddd,  $J$  = 7.7, 1.9, 1.1, 1H), 7.87 (ddd,  $J$  = 7.7, 1.9, 1.2, 1H), 7.74 (dd,  $J$  = 7.3, 1.9, 1H), 7.62 (t,  $J$  = 7.7, 1H), 7.10 (dd,  $J$  = 7.3, 5.0, 1H), 4.09 (s, 3H), 2.74 (s, 3H).

### 1-(4'-Ethoxy-3-biphenyl)ethenone




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.24 (t,  $J$  = 1.8, 1H), 7.98 (ddd,  $J$  = 7.7, 1.7, 1.1, 1H), 7.85 (ddd,  $J$  = 7.8, 1.9, 1.1, 1H), 7.68–7.63 (m, 2H), 7.60 (t,  $J$  = 7.7, 1H), 7.10–7.06 (m, 2H), 4.18 (q,  $J$  = 7.0, 2H), 2.75 (s, 3H), 1.55 (t,  $J$  = 7.0, 3H).

### 1-(3'-Ethoxy-3-biphenyl)ethenone




$^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 8.27 (t,  $J$  = 1.9, 1H), 8.03 (ddd,  $J$  = .7, 1.8, 1.2, 1H), 7.88 (ddd,  $J$  = 7.7, 1.9, 1.1, 1H), 7.63 (t,  $J$  = 7.7, 1H), 7.49–7.44 (m, 1H), 7.29 (ddd,  $J$  = 7.6, 1.7, 0.9, 1H), 7.24 (dd,  $J$  = 2.5, 1.7, 1H), 7.02 (ddd,  $J$  = 8.2, 2.5, 0.9, 1H), 4.21 (q,  $J$  = 7.0, 2H), 2.75 (s, 3H), 1.55 (t,  $J$  = 6.9, 3H).

### 1-(2'-Ethoxy-3-biphenyl)ethenone



$^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 8.29 (t,  $J$  = 1.8, 1H), 8.02 (dt,  $J$  = 7.8, 1.5, 1H), 7.86 (dt,  $J$  = 7.6, 1.4, 1H), 7.59 (t,  $J$  = 7.7, 1H), 7.47–7.39 (m, 2H), 7.14 (td,  $J$  = 7.5, 1.1, 1H), 7.09 (dd,  $J$  = 8.2, 1.1, 1H), 4.16 (q,  $J$  = 7.0, 2H), 2.73 (s, 3H), 1.46 (t,  $J$  = 7.0, 3H).


### 1-(4'-Methyl-2-biphenyl)ethenone



$^1\text{H NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 7.64 (dd,  $J$  = 7.7, 1.5, 1H), 7.63–7.54 (m, 1H), 7.52–7.46 (m, 2H), 7.33 (s, 4H), 2.51 (s, 3H), 2.47 (s, 3H).


Spectroscopic data in good agreement with the literature.<sup>[8]</sup>

### 1-(4'-Ethoxy-2-biphenyl)ethenone




$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 7.86–7.82 (m, 1H), 7.64–7.59 (m, 1H), 7.60–7.53 (m, 1H), 7.51–7.45 (m, 1H), 7.38–7.32 (m, 2H), 7.08–7.02 (m, 2H), 4.22 (q,  $J$  = 6.9, 2H), 2.11 (s, 3H), 1.56 (t,  $J$  = 6.9, 3H).

#### 1-(3'-Ethoxy-2-biphenyl)ethenone




$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 7.63 (dd,  $J$  = 7.4, 1.5, 1H), 7.60 (td,  $J$  = 7.5, 1.5, 1H), 7.52 (dd,  $J$  = 7.4, 1.2, 2H), 7.51–7.46 (m, 1H), 7.03 (ddd,  $J$  = 8.3, 2.5, 1.0, 1H), 7.01–6.99 (m, 1H), 6.98 (dd,  $J$  = 2.5, 1.6, 1H), 4.19 (d,  $J$  = 6.9, 2H), 2.13 (s, 3H), 1.53 (t,  $J$  = 7.1, 3H).

#### 1-(2'-Ethoxy-2-biphenyl)ethenone



$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 7.76–7.69 (m, 1H), 7.60 (td,  $J$  = 7.6, 1.5, 1H), 7.41 (s, 2H), 7.14 (dd,  $J$  = 7.5, 1.1, 1H), 7.04–7.00 (m, 3H), 4.07 (q,  $J$  = 7.0, 2H), 2.22 (s, 3H), 1.51 (t,  $J$  = 7.0, 3H).


#### 4-Methyl-4'-nitrobiphenyl



$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 8.39–8.35 (m, 2H), 7.83–7.80 (m, 2H), 7.65–7.60 (m, 2H), 7.40 (d,  $J$  = 7.9, 2H), 2.52 (s, 3H).


Spectroscopic data in good agreement with the literature.<sup>[9]</sup>

### 2-Methoxy-3-(4-nitrophenyl)pyridine



<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  = 8.40–8.36 (m, 2H), 8.34 (dd,  $J$ =5.0, 1.8, 1H), 7.86–7.83 (m, 2H), 7.76 (dd,  $J$ =7.3, 1.9, 1H), 7.13 (dd,  $J$ =7.3, 5.0, 1H), 4.04 (s, 3H).


### 4-Ethoxy-4'-nitrobiphenyl



<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.38–8.33 (m, 2H), 7.81–7.76 (m, 2H), 7.69–7.64 (m, 2H), 7.12–7.08 (m, 2H), 4.20 (q,  $J$  = 6.9, 2H), 1.55 (t,  $J$  = 7.0, 3H).


Spectroscopic data in good agreement with the literature.<sup>[7]</sup>

### 3-Ethoxy-4'-nitrobiphenyl




<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.40–8.36 (m, 2H), 7.84–7.80 (m, 2H), 7.49 (t,  $J$  = 7.9, 1H), 7.29 (ddd,  $J$  = 7.7, 1.8, 0.9, 1H), 7.24 (dd,  $J$  = 2.5, 1.7, 1H), 7.07 (ddd,  $J$  = 8.2, 2.5, 0.9, 1H), 4.21 (q,  $J$  = 7.0, 2H), 1.56 (t,  $J$  = 7.0, 3H).

### 2-Ethoxy-4'-nitrobiphenyl



$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 8.37–8.32 (m, 2H), 7.84–7.80 (m, 2H), 7.47 (ddd,  $J$  = 8.2, 7.4, 1.8, 1H), 7.44 (dd,  $J$  = 7.6, 1.7, 1H), 7.15 (td,  $J$  = 7.5, 1.1, 1H), 7.10 (dd,  $J$  = 8.3, 1.0, 1H), 4.17 (q,  $J$  = 7.0, 2H), 1.46 (t,  $J$  = 7.0, 3H).


#### 4'-Methyl-4-biphenylol



$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 7.54 (dd,  $J$  = 4.5, 2.0, 2H), 7.53–7.51 (m, 2H), 7.32–7.29 (m, 2H), 7.00–6.96 (m, 2H), 2.47 (s, 3H).


Spectroscopic data in good agreement with the literature.<sup>[10]</sup>

#### 2-Methoxy-3-(4-phenylol)pyridine




$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 8.21 (dd,  $J$  = 5.0, 1.9, 1H), 7.69 (dd,  $J$  = 2.0, 0.9, 1H), 7.55–7.50 (m, 2H), 7.04 (dd,  $J$  = 7.2, 5.0, 1H), 7.01–6.98 (m, 2H), 3.87 (s, 3H).

#### 4'-Ethoxy-4-biphenylol




$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 7.56–7.52 (m, 2H), 7.51–7.48 (m, 2H), 7.05–7.01 (m, 2H), 6.99–6.95 (m, 2H), 4.15 (q,  $J$  = 7.1, 2H), 1.52 (t,  $J$  = 7.0, 3H).

#### 3'-Ethoxy-4-biphenylol



$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 7.57–7.52 (m, 2H), 7.39 (t,  $J$  = 7.9, 1H), 7.21 (ddd,  $J$  = 7.7, 1.7, 1.0, 1H), 7.17 (dd,  $J$  = 2.5, 1.7, 1H), 7.01–6.97 (m, 2H), 6.92 (ddd,  $J$  = 8.2, 2.6, 0.9, 1H), 4.18 (q,  $J$  = 7.0, 2H), 1.53 (t,  $J$  = 7.0, 3H).

### 2'-Ethoxy-4-biphenylol



$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 7.41–7.35 (m, 3H), 7.01 (dt,  $J$  = 7.4, 1.1, 1H), 6.99 (dt,  $J$  = 7.8, 1.0, 2H), 6.83–6.78 (m, 2H), 4.13 (q,  $J$  = 7.0, 2H), 1.51 (t,  $J$  = 7.0, 3H).

All NMR spectra are available: <https://doi.org/10.7488/ds/3108>

## S14 References

- [1] M. J. Capeness, V. Echavarrri-Bravo, L. E. Horsfall, *Front. Microbiol.* 2019, **10**, 997.
- [2] S. S. Wang, *J. Am. Chem. Soc.* 1973, **95**, 1328.
- [3] D. A. Armbruster, T. Pry, *Clin. Biochem. Rev.* 2008, **29**, S49.
- [4] E. Alacid, C. Nájera, *Org. Lett.* 2008, **10**, 5011.
- [5] M. Tobisu, T. Xu, T. Shimasaki, N. Chatani, *J. Am. Chem. Soc.* 2011, **133**, 19505.
- [6] M. A. Pena, J. P. Sestelo, L. A. Sarandeses, *J. Org. Chem.* 2007, **72**, 1271.
- [7] P. Lan, D. Berta, J. A. Porco, M. S. South, J. J. Parlow, *J. Org. Chem.* 2003, **68**, 9678.
- [8] L. J. Goossen, N. Rodríguez, C. Linder, *J. Am. Chem. Soc.* 2008, **130**, 15248.
- [9] M. L. N. Rao, D. N. Jadhav, D. Banerjee, *Tetrahedron* 2008, **64**, 5762.
- [10] S. A. Moteki, J. M. Takacs, *Angew. Chem. Int. Ed.* 2008, **47**, 894.